Snake Venom Phospholipases A2: A New Class of Antitumor Agents | Bentham Science
Generic placeholder image

Protein & Peptide Letters

Editor-in-Chief

ISSN (Print): 0929-8665
ISSN (Online): 1875-5305

Snake Venom Phospholipases A2: A New Class of Antitumor Agents

Author(s): Renata S. Rodrigues, Luiz Fernando M. Izidoro, Robson J. de Oliveira Jr., Andreimar M. Soares, Veridiana M. Rodrigues and Suely V. Sampaio

Volume 16, Issue 8, 2009

Page: [894 - 898] Pages: 5

DOI: 10.2174/092986609788923266

Price: $65

Open Access Journals Promotions 2
Abstract

Phospholipases A2 (PLA2) are enzymes of high medical scientific interest due to their involvement in a large number of human inflammatory diseases. PLA2 constitute a diverse family of enzymes which catalyses the hydrolysis of the sn-2 ester bond in glycerophospholipids and exhibit a wide range of physiological and pathological effects. The ubiquitous nature of PLA2 highlights the important role they play in many biological processes, as cell signaling and cell growth, including the generation of proinflammatory lipid mediators such as prostaglandin and leukotrienes, regulation of lipid mediators. The activity and expression of several PLA2 isoforms are increased in several human cancers, suggesting that these enzymes have a central role in both tumor development and progression and can be targets for anti-cancer drugs. On the other hand, some PLA2 isolated from Viperidae venoms are capable to induce antitumoral activity. In summary PLA2 from snake venoms can be a new class of anticancer agents and provide new molecular and biological insights of cancer development.

Keywords: Snake venom, phospholipase A2, antitumor effect, VRCTC-310


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy